Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.
about
The promise of neuroprotective agents in Parkinson's diseaseEnergy failure: does it contribute to neurodegeneration?Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifyingA pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month resultsDesign innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.Treatment of mitochondrial disorders.Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.A review of creatine supplementation in age-related diseases: more than a supplement for athletes.Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic networkGestational and lactational iron deficiency alters the developing striatal metabolome and associated behaviors in young rats.Neuroprotective effects of 20(S)-protopanaxadiol against glutamate-induced mitochondrial dysfunction in PC12 cells.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Mechanism of nitrogen metabolism-related parameters and enzyme activities in the pathophysiology of autism.Combination Therapies for Traumatic Brain Injury: Retrospective ConsiderationsAgeing and neuronal vulnerability.Protection against Parkinson's disease progression: clinical experience.Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons.Serum Metabolomic Profiles in Neonatal Mice following Oral Brominated Flame Retardant Exposures to Hexabromocyclododecane (HBCD) Alpha, Gamma, and Commercial Mixture.Antioxidants in Huntington's disease.Age-Induced Alterations in Hippocampal Function and Metabolism.Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic miceHigh-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.Effect of co-enzyme Q10 and alpha-lipoic acid on response of rabbit urinary bladder to repetitive stimulation and in vitro ischemia.Human, rat and chicken small intestinal Na+ - Cl- -creatine transporter: functional, molecular characterization and localization.Hippocampal N-acetyl aspartate levels do not mirror neuronal cell densities in creatine-supplemented epileptic rats.Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study.Transcranial near-infrared photobiomodulation attenuates memory impairment and hippocampal oxidative stress in sleep-deprived mice.Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms.Mitochondrial Agents for Bipolar Disorder.
P2860
Q21129436-C072931F-EE78-494A-B288-68168A6E764AQ28389950-71873996-CC43-490F-A22E-0BB7CE165139Q28732683-F513A3BB-ECCB-4805-B638-D09A5EE4EA5DQ30407150-F977F0C1-827D-4178-829D-590777913360Q30417007-9BC10B84-BED2-44BD-B875-3EFE5E462674Q33794684-EAFF5B77-E220-4DAE-BB44-45070013EBCCQ33837238-29102074-9B95-4572-99CA-6E9849D4F3C7Q33917550-EEB17C33-EB45-47BB-A545-B23F9F236388Q35005568-31883F04-70A0-43B1-A5BF-5ABB1B54B33EQ35213003-E76D82CC-1C1F-4049-876C-4DDC9197C781Q35842661-D0A91B0C-45D7-47D4-9311-9E9A25E300C1Q35879291-67A2A18A-D444-4B01-B836-6881C5CF8D07Q35958359-73BE3F75-B709-4DAA-BC64-8CBBE318AF67Q36028894-8686A251-59C1-40CB-982C-13FBE5EE05C2Q36427698-DF2A077B-8324-4ACB-80AC-F6A99576F64AQ36428039-AAF1BEC4-2F1E-481F-B8FF-6E6F7378980DQ37131239-83BA80F1-BF3A-41E5-B64B-A985DD300B34Q37180789-4A29B0D0-1774-4AA6-AF0E-CDDC805B822DQ37738907-E4B45D0C-5BF9-470B-A561-7A162ADC03F0Q37964359-5346BF4D-9288-402E-94E4-131648425C6BQ39012774-0E01E36A-BBEC-4938-9BBC-8E7194DD679AQ40436889-FADBA165-5EE1-43A7-9865-F6A6BC285EE6Q41832396-F76F66E4-8A63-402C-B96C-745391270760Q42423694-5A6C9808-BD2F-4E07-BDE5-78585EF861C9Q44218024-2788402B-14E3-4786-BB0A-D2ECDB95018DQ44658205-45FD0997-E3EB-4D4F-92F4-CB4177C62EA7Q46416690-E1E95EA4-8EDA-4AC0-84A8-64C7E66769FCQ47648253-9B82A67A-FF6B-4EA9-B9DA-FEA259758B8FQ47711481-4FA1B8CC-1FF7-43A5-AFD9-E3657A01A6CCQ52621890-F8B3371F-80EF-4E7C-9408-507A8F370B81
P2860
Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Potential for creatine and oth ...... ion in neurological disorders.
@ast
Potential for creatine and oth ...... ion in neurological disorders.
@en
Potential for creatine and oth ...... ion in neurological disorders.
@nl
type
label
Potential for creatine and oth ...... ion in neurological disorders.
@ast
Potential for creatine and oth ...... ion in neurological disorders.
@en
Potential for creatine and oth ...... ion in neurological disorders.
@nl
prefLabel
Potential for creatine and oth ...... ion in neurological disorders.
@ast
Potential for creatine and oth ...... ion in neurological disorders.
@en
Potential for creatine and oth ...... ion in neurological disorders.
@nl
P356
P1433
P1476
Potential for creatine and oth ...... ion in neurological disorders.
@en
P2093
Tarnopolsky MA
P304
P356
10.1002/ANA.1028.ABS
P577
2001-05-01T00:00:00Z